Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545006 | 0.90 | GAA (0.56) | GAAHPGDLMNASRCBRAF | |
| SCHEMBL4521443 | 0.87 | PDE4A (0.46) | GAAHPGDLMNAALDH1A1MEN1 | |
| SCHEMBL10623704 | 0.86 | GAA (0.44) | GAAHPGDLMNAALDH1A1MAPK1 | |
| SCHEMBL14692506 | 0.86 | HTT (0.48) | GAAHPGDLMNAALDH1A1L3MBTL1 | |
| SCHEMBL4506277 | 0.85 | LMNA (0.65) | GAAHPGDLMNAALDH1A1MAPK1 | |
| SCHEMBL4518495 | 0.84 | PTGS2 (0.42) | GAAHPGDLMNAPOLBKMT2A | |
| SCHEMBL14483300 | 0.83 | MEN1 (0.61) | LMNAALDH1A1MAPK1L3MBTL1POLB | |
| SCHEMBL4523450 | 0.81 | RAB9A (0.55) | GAAHPGDLMNAALDH1A1MEN1 | |
| SCHEMBL5067031 | 0.80 | HPGD (0.73) | HPGDLMNASRCBRAFKDR | |
| SCHEMBL7101284 | 0.79 | GAA (0.65) | GAAHPGDLMNAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054413-A1 | Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| CN-101321758-A | Novel 5,6-dihydropyrazolo[3,4-e] [l,4]diazepin-4 (ih) -one derivatives for the treatment of asthma and chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | CN | disclosed |
| EP-1931672-A1 | NOVEL 5,6-DIHYDROPYRAZOLO[3,4-E] [L,4]DIAZEPIN-4 (IH) -ONE DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | AstraZeneca AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007040435-A1 | NOVEL 5,6-DIHYDROPYRAZOLO[3,4-E] [L,4]DIAZEPIN-4 (IH) -ONE DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054413-A1 | Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease | PDE4B, PDE4A, PDE12 | GAA 1597/4885HPGD 55/4885LMNA 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.